Drugs: musculoskeletal and joint diseases

High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission
Elizabeth G Araujo, Stephanie Finzel, Matthias Englbrecht, Dominik A Schreiber, Francesca Faustini, Axel Hueber, Kemal Nas, Juergen Rech, Georg Schett

Annals of the Rheumatic Diseases Apr 2015, 74 (4) 655-660; DOI: 10.1136/annrheumdis-2013-204229
Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice
Angel Lanas, Maarten Boers, Javier Nuevo

Annals of the Rheumatic Diseases Apr 2015, 74 (4) 675-681; DOI: 10.1136/annrheumdis-2013-204155
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
Iain B McInnes, Liz Thompson, Jon T Giles, Joan M Bathon, Jane E Salmon, Andre D Beaulieu, Christine E Codding, Timothy H Carlson, Christian Delles, Janet S Lee, Naveed Sattar

Annals of the Rheumatic Diseases Apr 2015, 74 (4) 694-702; DOI: 10.1136/annrheumdis-2013-204345
Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study
Burkhard Möller, Menno Pruijm, Sabine Adler, Almut Scherer, Peter M Villiger, Axel Finckh,

Annals of the Rheumatic Diseases Apr 2015, 74 (4) 718-723; DOI: 10.1136/annrheumdis-2013-204078
A8.9 Neutralisation of miR-155 ameliorates collagen-induced arthritis
BE Morton, S Neben, N Gibson, C McSharry, IB McInnes, M Kurowska-Stolarska

Annals of the Rheumatic Diseases Mar 2015, 74 (Suppl 1) A84-A85; DOI: 10.1136/annrheumdis-2015-207259.194
A8.14 CD39 and CD73 transgenic exosomes and recombinant fusion protein as novel therapeutics for the treatment of inflammatory disease
JD Finn, J van Ittersum, N Broekstra, PP Tak, MJ Vervoordeldonk

Annals of the Rheumatic Diseases Mar 2015, 74 (Suppl 1) A86-A87; DOI: 10.1136/annrheumdis-2015-207259.199
A8.12 AAV mediated expression of CD39 and CD73 is effective in reducing inflammation in the air pouch synovial inflammation model
JD Finn, S Snoek, J van Ittersum, N Broekstra, C Braam, E Kramer, M van Geldorp, PP Tak, MJ Vervoordeldonk

Annals of the Rheumatic Diseases Mar 2015, 74 (Suppl 1) A86; DOI: 10.1136/annrheumdis-2015-207259.197
A8.16 The cholinergic anti-inflammatory pathway does not influence sialadenitis or diabetes in the non-obese diabetic mouse model of SjÖgren’s syndrome
FA Koopman, N Roescher, JL Vosters, N Broekstra, PP Tak, MJ Vervoordeldonk

Annals of the Rheumatic Diseases Mar 2015, 74 (Suppl 1) A87-A88; DOI: 10.1136/annrheumdis-2015-207259.201
A8.15 ProS and Gas6 - two structurally related proteins with therapeutic effects in experimental arthritis, but via two different mechanisms
S Beermann, CEJ Waterborg, BT van den Brand, MB Bennink, MI Koenders, M de Vries, CV Rothlin, FAJ van de Loo

Annals of the Rheumatic Diseases Mar 2015, 74 (Suppl 1) A87; DOI: 10.1136/annrheumdis-2015-207259.200
A8.17 Effective use of bortezomib and plasma filtration in a critically ill patient with lupus nephritis and myocarditis: a case report and dynamics of (immuno) proteasome inhibition
MWP Tsang-A-Sjoe, KA de Groot, D Niewerth, J Cloos, JL Blank, S Zweegman, G Jansen, AE Voskuyl, JW van der Heijden

Annals of the Rheumatic Diseases Mar 2015, 74 (Suppl 1) A88; DOI: 10.1136/annrheumdis-2015-207259.202

Main menu

Drugs: musculoskeletal and joint diseases

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Drugs: musculoskeletal and joint diseases

Pages